Media

Press Releases

Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

March 2, 2023
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome

February 14, 2023
Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases

January 9, 2023
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 20, 2022
Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA

December 19, 2022

View More

Media Contacts

Ioana Piscociu

Senior Manager, Global Media Relations
+33 6 69 09 12 96

Craig Marks

Vice President, Investor Relations
+44 7584 349 193